A new Perspective published in npj Digital Medicine from CCAIM brings together academic and industry partners, led by Professor Mihaela van der Schaar, to explore how causal inference and digital twins could support more adaptive, efficient and patient-centred clinical trials.
The annual CCAIM Symposium showcased cutting-edge research from across the CCAIM community while bringing together experts from academia, healthcare and industry to discuss the future of AI in biomedicine.
CCAIM Announces Partnership with Takeda to Advance AI’s Impact in Pharmaceutical R&D.
AI-enabled clinical trials have been a core pillar of CCAIM’s vision from the beginning. Discover the research advancing more adaptive, personalised and intelligent clinical development.
Professor Mihaela van der Schaar will deliver a State-of-the-Art Keynote at EASL Congress 2026 in Barcelona, where she will discuss cutting-edge machine learning for liver health and how AI can move beyond static prediction toward systems that reason about disease progression, treatment response, patient heterogeneity, and clinical decision-making.
Nicolas Huynh and Prof David Bentley discuss their AISTATS 2026 paper on interpretable DNA sequence analysis, introducing DEFT — a framework that brings together accuracy and interpretability in genomics.
On 24 February 2026, CCAIM and Cambridge University Health Partners co-hosted “Partnering with Cambridge: AI to Revolutionise Clinical Trials” at the Ray Dolby Centre. The event brought together leaders from academia, industry, and regulation, marking an important first step in building closer collaboration around AI-enabled clinical trials.
Researchers from the Cambridge Centre for AI in Medicine have had a total of 11 papers accepted for the thirty-ninth Conference on Neural Information Processing Systems (NeurIPS) at the San Diego Convention Centre, 2 – 7 December 2025.
The CCAIM has published a landmark manifesto outlining how AI technologies – causal inference and digital twins – can transform clinical trials. This collaborative publication, co-authored with all CCAIM strategic partners – AstraZeneca, GSK, Sanofi, Boehringer Ingelheim, and QuantumBlack – charts a roadmap for faster, safer, and more inclusive medical research.
The Cambridge Centre for AI in Medicine (CCAIM) is pleased to announce a strategic collaboration with McKinsey & Company, and its artificial intelligence (AI) arm, QuantumBlack,… Read More »CCAIM Announces Strategic Collaboration with McKinsey & Company to Accelerate AI-Driven Innovation in Life Sciences and Healthcare